Is Prelude Therapeutics Inc (PRLD) overvalued? · rev $6.5M
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
This page asks whether Prelude Therapeutics Inc (PRLD) looks expensive on cached numbers — not a short thesis.
Latest reported PRLD revenue for 2025-09-30 was $6.5M. Net income was -$83.0M. Revenue was up 116.7% from 2024-09-30 to 2025-09-30. PRLD currently screens at market cap $346.5M.
PRLD currently screens at market cap $346.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next PRLD 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the PRLD stock page for the full model, not this heading.
Not investment advice.